Eli Lilly and Company (LLY)
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (88%) **Content type:** Clinical